Employer coverage for GLP-1 weight-loss drugs is declining, with many dropping these benefits by 2027. However, the FDA recently expanded the label for Eli Lilly's Mounjaro to include cardiovascular risk reduction in type 2 diabetes patients, strengthening its case for insurance coverage in diabetes management. This label does not affect obesity drug coverage but supports Lilly's argument that treating diabetes reduces costly hospital events. Despite price declines, Mounjaro's sales surged 91% in Q2, helping Lilly raise its full-year revenue forecast. The new label may protect diabetes-related reimbursements but is unlikely to reverse cuts in obesity drug coverage.
Novo Nordisk is rated as a Buy compared to Eli Lilly because it trades at a significant valuation discount of about 26% to its big pharma peers despite having similar growth rates and a strong dividend yield. The stock is priced at roughly 11.2 times...
Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...
Eli Lilly is rapidly growing its obesity and diabetes treatment portfolio, with its tirzepatide-based drugs Mounjaro and Zepbound generating nearly $15 billion in revenue and showing strong year-over-year growth of 91% and 46%, respectively. This gro...
Eli Lilly's most profitable stock entry points were during less hyped events like the 2008 ImClone acquisition and the 2014 Trulicity approval, yielding returns over 2,000%. In contrast, buying at the peaks of hype around blockbuster drugs Mounjaro a...
Eli Lilly (LLY) is recommended as a Strong Buy due to its attractive valuation and role as a diversification play for portfolios heavily invested in AI. Trading at about 24 times its 2027 earnings estimates, the stock is seen as premium but not overp...
